Skip to main content

LDN should be considered a first-line therapy for CFS/FM/Lyme

Speaker

Kent Holtorf, M.D

The presentation will review how LDN should be considered a first-line therapy for CFS/FM/Lyme and associated diseases and will discuss how it can be enhanced with other immune modulation therapies. Evidence will be presented on how a multisystem treatment protocol is a necessity for successful long-term treatment of these complex conditions. The cycle of dysfunction that results in multi-system dysfunction will be reviewed, as well as protocols that can be used as a starting point to treat these conditions.